The Medsintez Plant presented the first Russian veterinary insulin preparations at the VII International Conference “MOSM 2023”

From September 10 to 16, 2023, the 7th International Conference “Modern Synthetic Methodologies for Creating Drugs and Functional Materials” (MOSM 2023), dedicated to the 125th anniversary of the birth of Academician I.Ya. Postovsky, was held in Ekaterinburg and Perm. The Medsintez Plant took part in the business program of the conference and acted as a sponsor.

As a part of the international round table conference “Biotechnologies. Biomedicine. Biopharmaceuticals. Present and Future”, Alexander Lapin, Deputy Director for Science of Medsintez Plant LLC, delivered a report “Innovative biotechnological and biopharmaceutical tools in the creation of new generation preparations for veterinary and medical use at the production site of Medsintez Plant LLC”.

The Medsintez Plant has for 20 years specialized in developing and manufacturing pharmaceutical products that meet international GMP requirements and ISO standards. The Plant produces genetically engineered and analogue human insulin Rosinsulin®, veterinary insulin preparations, the first Russian recombinant follicle-stimulating hormone for treatment of infertility Primapur®, an innovative direct antiviral preparation Triazavirin® for treating influenza, ARVI and COVID-19, infusion solutions and solutions for automated apheresis, as well as substances produced through chemical and biotechnological synthesis.

The company is actively developing the biotechnological area for obtaining production strains of microorganisms and cell lines to produce pharmacologically active substances, technologies for their purification, including the formulation of drugs. The Plant’s latest achievements include the expansion of the product line of glycemic drugs for treating type I and II diabetes mellitus, as well as a package of preparations for treating infertility.

One of the priority development areas for the Medsintez Plant is the development of veterinary products, which is especially important in the current conditions of import substitution. Therefore, the most important aspect is the pharmaceutical development of new veterinary preparations, technologies and the organization of their production.

Currently, there is a shortage of imported preparations. The share of imported veterinary drugs is over 50% of the Russian market. Significant veterinary preparations include vaccines, serums, hormones, diagnostics, antibacterial, antiparasitic preparations, vitamins, etc.

The result of the research and production work done using biopharmaceutical and biotechnological approaches to the development of veterinary preparations is the creation of two new innovative species-specific insulin preparations — VINSUVET Glargine 50 IU for cats and VINSUVET MIX 100 IU for dogs.

The practical task of the Medsintez Plant for the next few years is to expand the range of biotechnological medical and veterinary products by creating new innovative medicines.